30 closest matches · ranked by relevance
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
High Grade Glioma
Primary: Response Rate
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 9.33; 7.62 Months
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Malignant Glioma
Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Glioblastoma Multiforme
Primary: Tumor-specific Cytotoxic T-cell Response — 0.496; 0.4836 10^9 cells/L
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With…
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Glioblastoma · Gliosarcoma · Supratentorial Glioblastoma
Primary: Overall Survival (OS) — 16.1; 15.7 months — p=0.11
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Brain Cancer
Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Glioblastoma Multiforme
Primary: Survival — 17.2 months — p=>.1
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Glioblastoma Multiforme of Brain
Primary: Safety and Tolerability — 19; 2; 2; 2 participants
Glioblastoma
Primary: Progression-Free Survival — 7.71 weeks
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants